De Jager R - Search Results

1

Phase II study of elliptinium in advanced breast cancer.

Rouësse JG, Le Chevalier T, Caille P, Mondesir JM, Sancho-Garnier H, May-Levin F, Spielmann M, De Jager R, Amiel JL. Rouësse JG, et al. Among authors: de jager r. Cancer Treat Rep. 1985 Jun;69(6):707-8. Cancer Treat Rep. 1985. PMID: 4016774

2

Inhibition of acetylcholinesterase and cholinesterase by ellipticine derivatives.

Alberici GF, Bidart JM, Moingeon P, Mondesir JM, Bohuon C, De Jager R. Alberici GF, et al. Among authors: de jager r. Biochem Pharmacol. 1983 Sep 15;32(18):2837-9. doi: 10.1016/0006-2952(83)90105-3. Biochem Pharmacol. 1983. PMID: 6626256 No abstract available.

3

High-dose cisplatin with fluid and mannitol-induced diuresis in advanced lung cancer: a phase II clinical trial of the EORTC Lung Cancer Working Party (Belgium).

De Jager R, Longeval E, Klastersky J. De Jager R, et al. Cancer Treat Rep. 1980;64(12):1341-6. Cancer Treat Rep. 1980. PMID: 6258791

4

Phase II clinical trial of VP-16-213 in ovarian cancer.

Maskens AP, Armand JP, Lacave AJ, De Jager RL, Hansen HH, Wolff JP. Maskens AP, et al. Among authors: de jager rl. Cancer Treat Rep. 1981 Mar-Apr;65(3-4):329-30. Cancer Treat Rep. 1981. PMID: 7016320 Clinical Trial. No abstract available.

5

Phase II study of 9-hydroxy-2N-methylellipticinium acetate.

Clarysse A, Brugarolas A, Siegenthaler P, Abele R, Cavalli F, de Jager R, Renard G, Rozencweig M, Hansen HH. Clarysse A, et al. Among authors: de jager r. Eur J Cancer Clin Oncol. 1984 Feb;20(2):243-7. doi: 10.1016/0277-5379(84)90190-1. Eur J Cancer Clin Oncol. 1984. PMID: 6538489

6

Phase II study of intravenous TZT-1027 in patients with advanced or metastatic soft-tissue sarcomas with prior exposure to anthracycline-based chemotherapy.

Patel S, Keohan ML, Saif MW, Rushing D, Baez L, Feit K, DeJager R, Anderson S. Patel S, et al. Cancer. 2006 Dec 15;107(12):2881-7. doi: 10.1002/cncr.22334. Cancer. 2006. PMID: 17109446 Free article. Clinical Trial.

7

A Phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with metastatic breast carcinoma.

Esteva FJ, Rivera E, Cristofanilli M, Valero V, Royce M, Duggal A, Colucci P, DeJager R, Hortobagyi GN. Esteva FJ, et al. Cancer. 2003 Sep 1;98(5):900-7. doi: 10.1002/cncr.11557. Cancer. 2003. PMID: 12942555 Free article. Clinical Trial.

8

An EORTC phase II study of mitoxantrone in solid tumors and lymphomas.

De Jager R, Cappelaere P, Armand JP, Keiling R, Fargeot P, Bastit P, van Glabbeke M, Renard J, Earl H, Rubens R, et al. De Jager R, et al. Eur J Cancer Clin Oncol. 1984 Nov;20(11):1369-75. doi: 10.1016/0277-5379(84)90055-5. Eur J Cancer Clin Oncol. 1984. PMID: 6542006

9

Phase II study of amsacrine in solid tumors: a report of the EORTC Early Clinical Trial-Group.

De Jager R, Siegenthaler P, Cavalli F, Klepp O, Bramwell V, Joss R, Alberto P, van Glabbeke M, Renard J, Rozencweig M, Hansen HH. De Jager R, et al. Eur J Cancer Clin Oncol. 1983 Feb;19(2):289-93. doi: 10.1016/0277-5379(83)90429-7. Eur J Cancer Clin Oncol. 1983. PMID: 6687457

10

Clinical trial of nafoxidine in advanced breast cancer.

Steinbaum FL, De Jager RL, Krakoff IH. Steinbaum FL, et al. Among authors: de jager rl. Med Pediatr Oncol. 1978;4(2):123-6. doi: 10.1002/mpo.2950040207. Med Pediatr Oncol. 1978. PMID: 661750

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

75 results

Search Page

Filters